Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$218.83 USD
+4.86 (2.27%)
Updated Jul 1, 2022 04:00 PM ET
3-Hold of 5 3
B Value A Growth D Momentum B VGM
Fundamental Charts
About Earnings Yield (TTM)
The company's trailing twelve month (TTM) Earning Yield is used to determine whether the company is undervalued or overvalued. The Earning yield an indicator of the company's earnings and the price paid for the stock. The calculation is the inverse of the P/E ratio. The most common use of the Earnings ratio is to compare it to other stocks and to compare the yields to the 10 Year T-Bill. If earnings go up, the yield goes up. If earnings go down, so does the yield. For example: If the yield on the S&P 500 is greater than the 10 Year T-Bill, stocks would be considered undervalued.
CRL 218.83 +4.86(2.27%)
Will CRL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that nearly triples the S&P 500.
Zacks News for CRL
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
Charles River (CRL) Prospers Internationally Amid FX Headwind
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
Why Is Charles River (CRL) Down 1.2% Since Last Earnings Report?
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Other News for CRL
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
Charles River Laboratories opens manufacturing facility in Cheshire, UK
Charles River opens Plasmid DNA Centre in Cheshire
Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Charles River Laboratories International Now #440 Largest Company, Surpassing Host Hotels & Resorts